HealthExec July 12, 2024
Drug manufacturer Eli Lilly has agreed to buy Morphic, a biopharma company that specialize in the management of inflammatory chronic illnesses. The $3.2 billion deal will bolster Eli Lilly’s portfolio of inflammatory bowel disease (IBD) treatments, as the deal includes MORF-057, Morphic’s new drug that is currently in a Phase II study for management of ulcerative colitis and Crohn’s disease.
IBD collectively refers to those two conditions, both characterized by chronic inflammation of the gastrointestinal tract as a result of an immune system reaction. Classified as an inhibitor of α4β7 integrin, MORF-057 used as an oral treatment has the potential in improving outcomes for patients struggling with these conditions, Morphic said in a statement.
“We...
Today's Sponsors
Today's Sponsor